

TP53 and P16^{INK4A}, but not H-KI-RAS, are Involved in Tumorigenesis and Progression of Pleomorphic Adenomas

CLAUDIA AUGELLO,¹ VALTER GREGORIO,¹ VIVIANA BAZAN,¹ PATRIZIA CAMMARERI,¹ VALENTINA AGNESE,¹ SANDRA CASCIO,^{1,2} SIMONA CORSALE,^{1,3} VALENTINA CALÒ,¹ ARIANNA GULLO,¹ RITA PASSANTINO,⁴ GRAZIA GARGANO,¹ LOREDANA BRUNO,¹ GAETANA RINALDI,¹ VINCENZA MORELLO,⁴ ALDO GERBINO,³ ROSA MARIA TOMASINO,⁴ MARCELLA MACALUSO,² EVA SURMACZ,² AND ANTONIO RUSSO^{1*}

¹Department of Oncology, Università of Palermo, Palermo, Italy

²Sbarro Institute for Cancer Research and Molecular Medicine,

College of Science and Technology, Temple University, Philadelphia

³Histological and Embriological Section, Department of Experimental Medicine, Institute of Pathology, Università of Palermo, Palermo, Italy

⁴Institute of Pathology, Università of Palermo, Palermo, Italy

The putative role of *TP53* and *p16^{INK4A}* tumor suppressor genes and Ras oncogenes in the development and progression of salivary gland neoplasias was studied in 28 cases of pleomorphic adenomas (PA), 4 cases of cystic adenocarcinomas, and 1 case of carcinoma ex-PA. Genetic and epigenetic alterations in the above genes were analyzed by Polymerase Chain Reaction/Single Strand Conformational Polymorphism (PCR/SSCP) and sequencing and by Methylation Specific-PCR (MS-PCR). Mutations in *TP53* were found in 14% (4/28) of PAs and in 60% (3/5) of carcinomas. Mutations in H-Ras and K-Ras were identified in 4% (1/28) and 7% (2/28) of PAs, respectively. Only 20% (1/5) of carcinomas screened displayed mutations in K-Ras. *p16^{INK4A}* promoter hypermethylation was found in 14% (4/28) of PAs and 100% (5/5) carcinomas. All genetic and epigenetic alterations were detected exclusively in the epithelial and transitional tumor components, and were absent in the mesenchymal parts. Our analysis suggests that *TP53* mutations and *p16^{INK4A}* promoter methylation, but not alterations in the *H-Ras* and *K-Ras* genes, might be involved in the malignant progression of PA into carcinoma. *J. Cell. Physiol.* 207: 654–659, 2006. © 2006 Wiley-Liss, Inc.

Salivary gland (SG) neoplasias are quite rare, accounting for approximately 2–3% of head and neck tumors (De Vita et al., 2001). Most SG tumors are benign and are generally pleomorphic adenomas (PAs). SG tumors are characterized by an extremely varied histomorphological phenotype due to combinations of different epitheliomorphic and mesenchymomorphic features. The molecular mechanisms determining these two histomorphological types and their coexistence in SG tumors are not fully understood, with many aspects of their histogenesis still under discussion. Two relevant theories have been proposed: the “different cell” theory suggests that SG neoplasias originate from two distinct cell populations, that is, mesenchymal and (myo-) epithelial (Soini and Autio-Harmanen, 1993; Su et al., 1993). The “single-cell” theory suggests that SG tumors develop in the process of epithelial–mesenchymal transition (Welsh and Meyer, 1968; Dardick et al., 1983).

Approximately 2–9% of PAs become malignant, evolving into carcinoma ex-pleomorphic adenoma that is characterized by frequent infiltrations of the surrounding parenchyma and metastatic spreading (Chen, 1978; Gnepp, 1993; Ellis and Auclair, 1995). The most common form of SG malignancy is the cystic adenoid carcinoma, a fairly slow-growing tumor with a tendency for perineural invasion and hematogenous metastasis to the lungs and bones (Bell et al., 2005).

The critical role of different genetic and epigenetic alterations in carcinogenesis has been recognized for some time; some of the most important events in the transformation of normal cells into malignant cells involve mutations in genes encoding the Ras family proteins (Giehl, 2005) and the oncosuppressor *TP53*

(Papadaki et al., 1996; Steele et al., 1998) as well as the methylation of the *p16^{INK4A}* gene promoter (Das and Singal, 2004). Little is known about their role in the development of SG tumors (Kishi et al., 2005).

Consequently, the aim of our study was to analyze the frequency of *TP53*, *H-Ras*, and *Ki-Ras* gene alterations and to assess the methylation status of the *p16^{INK4A}* gene promoter in SG tumors. Furthermore, we examined whether these genetic and epigenetic alterations were associated with epithelial or mesenchymal SG tissue components.

MATERIALS AND METHODS

Study design

A prospective study was performed on tumor samples from a consecutive series of 33 patients who underwent resective surgery for primary operable SG at the Department of Oncology, University of Palermo, Italy. All resection specimens and microscopic slides were examined by two independent pathologists (R.M.T. and V.M.) who were blinded to the original diagnosis and the results of molecular analyses. The complete excision of the primary tumor was histologically proven by examination of the resected margins. The study

Claudia Augello and Valter Gregori have contributed equally to this work.

*Correspondence to: Antonio Russo, MD, Via Veneto 5, 90144 Palermo, Italy. E-mail: Lab-oncobiologia@usa.net

Received 25 October 2005; Accepted 2 December 2005

DOI: 10.1002/jcp.20601

material included 28 PAs, 4 cystic adenocarcinomas, and 1 carcinoma ex-pleomorphic adenoma. Tissues were fixed in 70% ethyl alcohol and paraffin-embedded. At least three single sections were analyzed from each paraffin-embedded tissue. One of the sections was used for microdissection followed by mutational analysis, while the others were used for immunohistochemistry experiments.

Laser-pressure catapulting (LPC) and DNA extraction

Five-micrometer sections of paraffin-embedded tissue specimens, prepared using a microtome, were mounted on the supporting LPC membrane placed on the slide. The samples were pretreated with xylene for 10 min and rehydrated using decreasing grade alcohols (100%, 95% 50% ethanol) and H₂O. Then the slides were stained with hematoxylin and eosin and dehydrated using increasing graded alcohol. LPC was performed using a Zeiss inverted microscope PALM Laser Micro-Beam System UV laser at 337 nm. Before performing microdissection, 1 μ l of mineral oil was placed on the samples (Bazan et al., 2005b). The areas to be dissected were selected by means of extremely high-precision microcuts (the specimens ranged from as little as 1 μ m to 1,000 μ m in diameter). LPC dissection was performed using a few shots each of 100 μ m in diameter. After catapulting, the material was removed from the cap for genetic analysis. Genomic DNA from tumor and normal specimens was extracted using the QIAamp Tissue Kit (Qiagen, Hilden, Germany) following standard protocol.

Detection of TP53, H-Ras and Ki-Ras gene mutations

Normal and tumor samples were used to screen for mutations within the *TP53*, *Ki-Ras*, and *H-Ras* genes using Single Strand Conformational Polymorphism (SSCP) analysis. PCR amplification of the exons 5–8 for TP53 and exon 1 for H-Ras and K-Ras (Table 1) was performed as previously described (La Farina et al., 1998). The abundance and integrity of the amplification products were verified by 1.5% agarose gel electrophoresis and ethidium bromide staining. One hundred nanogram aliquots of the PCR products, purified and concentrated by filtration through Microcon 50 columns (Amicon, Beverly, MA), were denatured and used for SSCP analysis. Individual ssDNA fragments exhibiting shifted mobilities relative to normal controls, were electroeluted from polyacrylamide gel, as described previously (Russo et al., 2002), reamplified, and sequenced. The characterization of single mutations was performed by automated sequencing using the Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and the model 3100 DNA sequencer (Perkin-Elmer, Foster City, CA).

Cytokeratin and vimentin immunohistochemistry

Paraffin-embedded sections from alcohol-fixed tissues of all PA cases were immunostained with monoclonal antibodies (Abs) against cytokeratin and vimentin in order to identify the epithelial and mesenchymal components, respectively. Two micrometer sections were pretreated with xylene for 10 min

and rehydrated using decreasing graded alcohols (100%, 95%, 50%, ethanol) and H₂O. Endogenous peroxidase activity was blocked by incubating the samples in 3% hydrogen peroxide for 10 min followed by a phosphate-buffered saline (PBS) wash. The sections were then simultaneously immunostained with a mixture of monoclonal Abs against cytokeratin (clone MNF116, dilution 1:50, Dako, Denmark) and vimentin (clone V9, dilution 1:100, BioGenex, Netherlands) for 30 min at room temperature. Applying the indirect peroxidase-antiperoxidase (PAP) method by a standard peroxidase-labeled streptavidin-biotin procedure (LSAB+System-HRP, Dako), the sections were incubated with the biotinylated secondary Ab and then with a mix of streptavidin-horseradish peroxidase-labeled. Detection of the antigens was performed with the use of AEC Substrate-Chromogen kit (Dako-AEC); the slides were then counterstained with Meyer's hematoxylin.

Methylation status of p16^{INK4A} locus

Normal and tumor samples were analyzed using the CpGenome DNA Modification kit (Intergene Company) following manufacturer's instructions. Peripheral blood leukocytes (PBL) were used as negative controls and universal methylated DNA (ONCOR, Geithersburg, MD) was used as a positive control. DNA was modified with bisulfite treatment. Specifically, 2 μ g of DNA were denatured using 0.2 M NaOH for 10 min at 37°C. Then, DNA Modification Reagent I was added and the mixture was incubated for 18 h at 50°C, and subsequently treated with DNA Modification Reagents II and III in 50 μ l of water. The modification of DNA was completed with 0.3 M NaOH treatment for 5 min, followed by ethanol precipitation. The modified DNA was amplified by PCR using specific primers (Table 1) to distinguish methylated and unmethylated regions. The size and integrity of the amplification products were verified by 2% agarose gel electrophoresis and ethidium bromide staining.

RESULTS

Analysis of genetic and epigenetic alterations in SG tumors

TP53 mutations. The mutational analyses of exons 5 to 8 of the *TP53* gene identified 8 TP53 alterations in 28 (28%) PAs screened. The particular features of these alterations are shown in Table 2. Twenty-five percent (2/8) of the mutations were found in exon 5, 50% (4/8) in exon 6 and 25% (2/8) in exon 7; no mutations were identified in exon 8. All mutations were single-nucleotide substitutions. 50% percent of TP53 mutations were missense (4/8), and 50% (4/8) were silent mutations. Among these alterations, transversions (7/8, 87%) were far more frequent than transitions (1/8, 13%) (Fig. 1) (Table 2). One mutation occurred in highly conserved domains (areas II–V). Considering the specific functional and structural domains of TP53 protein (Cho et al., 1994), one mutation occurred in the L2 loop.

In the cases of carcinoma ex-pleomorphic adenoma and cystic adenoid carcinomas, 4 TP53 mutations were found; 50% (2/4) of those occurred in exon 5, 25% (1/4) in exon 6, and 25% (1/4) in exon 7. All mutations proved to be single-nucleotide substitutions, of which 75% (3/4) were missense mutations, and 25% (1/4) encoded silent mutations (Table 2). All (4/4) mutations were transversions. Twenty-five percent of the mutations (1/4) occurred in highly conserved TP53 domains. Functionally, 25% of mutations (1/4 cases) were in the L2 loop and 25% in the L3 loop.

H-Ras and Ki-Ras mutations. In the analyzed PA cases, 4% (1/28) and 7% (2/28) of the missense mutations were found in codon 13 of H-Ras and Ki-Ras, respectively. A high number of cases 8/28 (28%) displayed a silent mutation in exon 1 (codon 27 His27His CAT>CAC) of H-Ras. In the SG carcinomas analyzed, we identified a missense mutation in codon 13 in one

TABLE 1. Oligonucleotide primers for p53, H-ras, K-ras, and p16 genotyping

Exon	Primer sequences	Anneal, °C
ex5 p53	5'-caa cca gcc ctg teg tct ctc-3'	58
	5'-ctg ttc act tgt gcc ctg ac-3'	
ex6 p53	5'-cct cac tga ttg ctc tta gg-3'	50
	5'-agt tgc aaa cca gac etc a-3'	
ex7 p53	5'-caa gtg get cct gac ctg ga-3'	58
	5'-tcc tag gtt ggc tct gac-3'	
ex8 p53	5'-tcc tgc ttg ctt acc tcg-3'	54
	5'-tcc tat cct gag tag tgg t-3'	
h-ras	5'-ctg agg agc gat gac gga ata taa gc-3'	68
	5'-ctc tat agt ggg gtc gta ttc gtc ca-3'	
k-ras	5'-gtg tga cat gtt cta ata tag tca ca-3'	58
	5'-gaa tgg tcc tgc acc agt aa-3'	
p16M	5'-tta tta gag ggt ggg gcg gat cgc-3'	61
	5'-gac ccc gaa ccg cga ccg taa-3'	
p16U	5'-tta tta gag ggt ggg gtg gat tgt-3'	66
	5'-cca ccc caa acc aca acc ata a-3'	

TABLE 2. TP53, K-H ras, p16INK4 genotyping data^a

Case	Diagnosis	TP53 mutation	Kras mutation	Hras mutation	p16INK4 alteration
1	Pleomorphic adenoma	WT	WT	Mut Gly13Ala GGT>CGT	M
2	Pleomorphic adenoma	WT	WT	WT	U
3	Pleomorphic adenoma	WT	WT	WT	U
4	Pleomorphic adenoma	WT	Mut Gly13Ala GGC>GCC	WT	M
5	Pleomorphic adenoma	WT	WT	WT	U
6	Pleomorphic adenoma	WT	WT	WT	U
7	Pleomorphic adenoma	WT	WT	WT	U
8	Pleomorphic adenoma	WT	WT	Pol His27His CAT>CAC	U
9	Pleomorphic adenoma	WT	WT	WT	U
10	Pleomorphic adenoma	WT	WT	WT	U
11	Pleomorphic adenoma	Pol ex6 Arg213Arg CGA>CGG	WT	Pol His27His CAT>CAC	U
12	Pleomorphic adenoma	WT	WT	WT	U
13	Pleomorphic adenoma	WT	WT	WT	U
14	Pleomorphic adenoma	WT	WT	WT	U
15	Pleomorphic adenoma	Mut ex5 Val143Met GTG>ATG Mut ex7 His233Pro CAC>CCC	WT	WT	U
16	Pleomorphic adenoma	Mut ex5 Pro128Ala CCT>GCT Pol ex6 Arg213Arg CGA>CGG	WT	WT	U
17	Pleomorphic adenoma	WT	WT	WT	M
18	Pleomorphic adenoma	WT	WT	Pol His27His CAT>CAC	U
19	Pleomorphic adenoma	WT	WT	WT	M
20	Pleomorphic adenoma	Mut ex5 Ser166Pro TCA>CCA	WT	WT	U
21	Pleomorphic adenoma	WT	WT	WT	U
22	Pleomorphic adenoma	WT	WT	Pol His27His CAT>CAC	U
23	Pleomorphic adenoma	WT	WT	WT	U
24	Pleomorphic adenoma	WT	WT	WT	U
25	Pleomorphic adenoma	Pol ex6 Arg213Arg CGA>CGG	WT	WT	U
26	Pleomorphic adenoma	WT	WT	Pol His27His CAT>CAC	U
27	Pleomorphic adenoma	WT	WT	Pol His27His CAT>CAC	U
28	Pleomorphic adenoma	Pol ex6 Ser211Ser CGA>CGG	Mut Gly13Ala GGC>GCC	Pol His27His CAT>CAC	U
29	Adenoid cystic carcinoma	WT	WT	WT	M
30	Adenoid cystic carcinoma	Pol ex6 Ser211Ser CGA>CGG	WT	WT	M
31	Adenoid cystic carcinoma	Mut ex5 Ser166Pro TCA>CCA Mut ex7 Arg249Ser AGG>AGT	WT	Pol His27His CAT>CAC	M
32	Adenoid cystic carcinoma	Mut ex5 Val143Met GTG>ATG	WT	Mut Gly13Ala GGT>CGT	M
33	Adenoid pleomorphic carcinoma	WT	WT	Pol His27His CAT>CAC	M

^aWT, wild-type; Mut, mutation; Pol, polymorphism; ex, exon; M, methylated; U, unmethylated.

case (25%), and silent mutations in codon 27 of H-Ras in two cases (50%). No mutations in Ki-Ras were observed (Table 2).

Methylation status of the p16^{INK4a} gene. The analysis of the methylation status of the p16^{INK4a} gene promoter revealed that 14% (4/28) of the PAs examined showed aberrant methylation within the CpG island. Furthermore, in all the cases (5/5) of carcinoma examined, we found hypermethylation of the p16^{INK4a} promoter (Fig. 2) (Table 2).

Multiple genetic and epigenetic alterations. Multiple alterations were found in 10% (3/28) of the analyzed PA cases; one case presented a double mutation in exons 5 and 7 of TP53 (codon 143 Val-Met, GTG>ATG and codon 233 Ist-Pro CAC>CCC), while the remaining cases showed methylation of the p16^{INK4a} promoter as well as alterations in exon 1 of both H-Ras (codon 13 Gly-Ala GGT>CGT) and Ki-Ras (codon 13 Gly-Ala GGC>GCC).

It is interesting to note that two triple alterations were observed in the five cases of carcinoma examined. Specifically, in addition to the methylation of p16^{INK4a}, our study showed either a double mutation of TP53 gene (codon 166 Ser-Pro TCA>CCA and codon 249 Arg-Ser AGG>AGT) or single mutation of TP53 gene (codon 143 Val-Met GTG>ATG) and H-Ras (codon 13 Gly-Ala GGT>CGT) (Table 2).

Analysis of genetic and epigenetic alterations in the epithelial and mesenchymal components

In the examined PA cases, only the epithelial component exhibited H-Ki-Ras missense mutations, TP53

mutation, and methylation of the p16^{INK4a} promoter, whereas the mesenchymal and transitional cells were not mutated. All H-Ki Ras and TP53 mutations, and p16^{INK4a} methylations detected occurred in the epithelial component of the tumor, as defined by immunohistochemistry prior to microdissection. In the mesenchymal areas, which were negative for cytokeratin, and positive for mesenchymal markers, no genetic alterations in H-Ki-Ras, TP53, and p16^{INK4a} were detected (Figs. 2 and 3).

DISCUSSION

Substantial clinical and experimental evidence supports the claim that alterations in the TP53 and p16^{INK4a} tumor suppressor genes and in Ras oncogenes play a critical role in tumorigenesis (Serrano et al., 1996; Bazan et al., 2002; Iacopetta, 2003). The importance of TP53 and Ras gene mutations has been particularly well defined in the model of colorectal cancer (CRC) (Fearon and Vogelstein, 1990; Hsieh et al., 2005) where both of these alterations are now accepted prognostic markers (Russo et al., 2005). Furthermore, specific TP53 mutations, more than any mutations, are biological indicators of CRC progression and outcome (Bazan et al., 2005a). The alteration in the gene encoding p16^{INK4a} has been well studied in different types of tumors, especially in melanoma and pancreatic cancer where it plays an important role during tumorigenesis or tumor progression (Bartsch et al., 1995; Bahuau et al., 1998).

Until now, only few studies examined the above genetic alterations in SG tumors. These limited data have not explained the role that TP53, Ras and p16^{INK4a}




Fig. 1. SSCP analysis of exons 5 and 7 (A and B) of *TP53* gene amplified from adenoid cystic carcinoma (Case 31) and genomic DNA from normal tissue from one patient (Case 29). In A and B, tumor DNA is on the right (WT) and normal tissue DNA is on the left (N). The extra bands visualized by SSCP correspond to ssDNA molecules harboring mutations in exon5 Ser166Pro TCA>CCA and in exon7 Arg249Ser AGG>AGT, as confirmed by sequencing (C and D).




Fig. 2. p16^{INK4a} analysis using MSP in one pleomorphic adenoma (Case 4). Bisulfite-treated DNA (which changes the unmethylated but not the methylated cytosines into uracil) is subjected to PCR amplification using primers designed to anneal specifically to the methylated bisulfite-modified DNA. MSP results are expressed as unmethylated p16^{INK4a}-specific bands (U) or methylated p16^{INK4a}-specific bands (M). Normal lymphocytes (NL) and in vitro methylated DNA (IVD) are used as negative and positive controls, respectively. Case 4 with methylated p16^{INK4a} within the epithelial tumor (Cyt, cytokeratin), but not in the mesenchymal component (Vim, vimentin). The last lane contains 100 bp DNA ladder.




Fig. 3. Typical image of the LPC process involving epithelial tissue immunostained with mAbs against cytokeratin placed on a slide after the addition of a 1 μ l of mineral oil. A and B: Cutting and catapulting of the gland. The images are at 40 \times magnification; (C) catapulted gland on the eppendorf cap; 5 \times magnification. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

might play in the etiology and progression of SG tumors. In addition, our study is the first one addressing the possible cooperation of the studied genetic and epigenetic alterations in SG cancer progression.

Point mutations in the *TP53* tumor suppressor gene are the most common cancer-related genetic abnormality in human malignancy. Previous analyses of different types of tumors have shown that most of *TP53* mutations affect exons 5–8, especially residues 130–286 encoding *TP53* DNA-binding domain and the region controlling folding and stabilization of tertiary structure. Only rarely have mutations outside exons 5–8 been identified, including those in the introns of the splicing sites, which probably give rise to an aberrant RNA splicing (18). We found a fairly high rate (14%) of mutations in *TP53* DNA, which is higher than the rate of mutations (10%) reported in the single published study on the subject (Weber et al., 2002a). The higher incidence of *TP53* mutations observed by us could be related to a more sensitive and accurate methodology (SSCP and then sequencing) (15), when compared with methodology (direct sequencing) used by other authors. Also, the phenotype of SG tumors examined could reflect different environmental and dietary factors, which might contribute to the cancerogenesis (Zheng et al., 1996).

Normal growth factor-dependent Ras signaling can be bypassed by mutations in codons 12, 13, and 61, leading to functional redundancy of the intrinsic activity of GTPase and constitutive activation of downstream pathways and, in consequence, increased mitogenesis (Milasin et al., 1993; Okutsu et al., 1993). The role of Ras oncogenes in SG tumors, and particularly in PAs, is still not fully understood. In fact, no published reports addressed the frequency of mutations in exon 1–2 in the *K-Ras* gene in such tissue. Our present study, which shows a mutation rate of 7%, is therefore the first relevant work. By analyzing exon 1 of H-Ras, we identified a missense mutation rate of 4% and a silent mutation rate of 28%; the latter type of alteration is often found in the healthy population (Perrone et al., 2003). Notably, the H-Ras alterations in PA were reported in only one previous study that employed hybridization with synthetic oligonucleotide probes (Milasin et al., 1993).

The p16^{INK4a} tumor suppressor gene is inactivated by mutation, homozygous deletion, or gene methylation. It has been shown that hypermethylation of the p16^{INK4a} promoter is frequent in some primary tumors such as lung, pancreatic cancer (Sherr and McCormick, 2002).

A recent study of 42 cases of PA of SG has shown that p16^{INK4a} does not present microdeletions or specific mutations in any exon, but in 28% of cases there was

methylation of the p16^{INK4a} promoter, which correlated with loss of mRNA transcription (Weber et al., 2002b). Our present analyses showed a hypermethylation rate of 14% of the promoter of the tumor oncosuppressor gene p16^{INK4a}. This difference between our study and the other report is probably due to dietary habits (Davis and Uthus, 2004).

The population of adenoid cystic carcinomas and carcinoma ex-pleomorphic adenoma analyzed by us included several tumors that probably originated from preceding pleomorphic adenomas. In accordance with previously published reports, these tumors were characterized by a high rate of TP53 missense mutations (three of five cases) a fairly high rate of H-Ras missense mutations (one of five cases), and a low rate of K-Ras mutations (one of five cases). In fact, some authors described a fairly high percentage of TP53 gene mutations in salivary gland carcinomas, (66–22%) (Papadaki et al., 1996; Zhang et al., 2004), while K-Ras and H-Ras mutations were found in 5–35% and 0–8% of salivary gland carcinoma cases (Yamamoto et al., 1996; Yoo and Robinson, 2000).

In our study, we described methylation of the p16^{INK4a} promoter in five out of five cases. Other reports described the different rates of p16^{INK4a} promoter methylation in SG tumors, from 11% to 47% (Nishimine et al., 2003; Li et al., 2005). It is possible that these data differ from our own because their studies were performed without the use of microdissection techniques and also because they refer to analyses regarding Oriental populations.

Very little is known about the molecular mechanisms of carcinogenesis in SG tumors developing from PAs. We carried out separate analysis of mesenchymal and epithelial components obtained by immunohistochemistry followed by microdissection, not only in order to distinguish the epithelial, mesenchymal, and transitional areas, but also to avoid false-positive or false-negative results, which may often be brought about by contamination with inflammatory cells or fibrotic areas. As Weber et al. (2002b) have already reported, in PAs, methylation of p16^{INK4A} and TP53 mutations occur only in the epithelial component, which suggests that it is these areas of the adenoma which potentially evolve into a carcinoma.

In conclusion, our analysis found a low rate of H-Ras and Ki-Ras missense mutations in all types of SG tumors studied, suggesting that the Ras oncogenes might be not involved in the malignant evolution of SG PA into SG carcinoma. On the other hand, the frequency of TP53 mutations and methylation of the p16^{INK4A} was significantly greater compared to that of Ras mutations. Moreover, we observed the accumulation of alterations in these genes in SG carcinomas. Thus, future analyses of TP53 mutations and p16^{INK4A} methylation might be useful for discriminating between benign and malignant SG tumors and to evaluate the prognostic value of these mutations.

ACKNOWLEDGMENTS

We thank Pamela Gardner for help in the preparation of the text.

LITERATURE CITED

Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M. 1998. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. *Cancer Res* 58:2298–2303.
 Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA, Jr., Goodfellow PJ. 1995. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. *Genes Chr Cancer* 14:189–195.

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A. 2002. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. *Ann Oncol* 13(9):1438–1446.
 Bazan V, Agnese V, Corsale S, Calo V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A. 2005a. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. *Ann Oncol* 16(Suppl 4):iv50–iv55.
 Bazan V, La Rocca G, Corsale S, Agnese V, Macaluso M, Migliavacca M, Gregorio V, Cascio S, Sisto PS, Di Fede G, Buscemi M, Fiorentino E, Passantino R, Morello V, Tomasino RM, Russo A. 2005b. Laser pressure catapulting (LPC): Optimization LPC-system and genotyping of colorectal carcinomas. *J Cell Physiol* 202(2):503–509.
 Bell RB, Dierks EJ, Homer L, Potter BE. 2005. Management and outcome of patients with malignant salivary gland tumors. *J Oral Maxillofac Surg* 63(7):917–928.
 Chen KTK. 1978. Metastasizing pleomorphic adenoma of the salivary gland. *Cancer* 42:2407–2411.
 Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. *Science* 265(5170):346–355.
 Dardick I, Van Nostrand AWP, Jeans NTD, Rippstein P, Edwards V. 1983. Pleomorphic adenoma. Ultrastructural organization of 'epithelial' regions. *Hum Pathol* 14:780–797.
 Das PM, Singal R. 2004. DNA methylation and cancer. *J Clin Oncol*, Review 22(22):4632–4642.
 Davis CD, Uthus EO. 2004. DNA Methylation, Cancer Susceptibility And Nutrient Interactions. *Experimental Biology and Medicine* 229:988–995.
 De Vita VT, Hellman S, Rosenberg SA. 2001. *Cancer principles & practice of oncology*. 6th edition. Philadelphia: Lippincott Williams & Wilkins.
 Ellis GL, Auclair PL. 1995. Tumors of the Salivary Glands. In: *Atlas of tumors pathology*, 3rd series, Fascicle 17. Washington, DC: Armed Forces, Institute of Pathology. pp. 39–57.
 Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. *Cell* 61:759–767.
 Gielh K. 2005. Oncogenic Ras in tumour progression and metastasis. *Biol Chem* 386(3):193–205.
 Gnepp DR. 1993. Malignant mixed tumors of the salivary glands: A review. *Pathol Annu* 28:279–328.
 Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, Huang YS, Huang CJ, Wang JY. 2005. APC, K-ras, and p53 gene mutations in colorectal cancer patients: Correlation to clinicopathologic features and postoperative surveillance. *Am Surg* 71(4):336–343.
 Iacopetta B. 2003. TP53 mutation in colorectal cancer. *Hum Mutat* 21(3):271–276.
 Kishi M, Nakamura M, Nishimine M, Ikuta M, Kirita T, Konishi N. 2005. Genetic and epigenetic alteration profiles for multiple genes in salivary gland carcinomas. *Oral Oncol* 41(2):161–169.
 La Farina M, Maturi N, Stira S, Russo A, Bazan V, Albanese I. 1998. Direct identification of each specific mutation in codon 12 and 13 of c-ki-ras2 by SSCP analysis. *Biochem Biophys Res* 246(3):813–815.
 Li J, El-Naggar A, Mao L. 2005. Promoter methylation of p16(INK4a), RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. *Cancer* 104(4):771–776.
 Milasin J, Pujic N, Dedovic N, Gavric M, Vranic V, Petrovic V, Mimic A. 1993. H-ras gene mutations in salivary gland pleomorphic adenomas. *Int J Oral Maxillofac Surg* 22(6):359–361.
 Nishimine M, Nakamura M, Kishi M, Okamoto M, Shimada K, Ishida E, Kirita T, Konishi N. 2003. Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. *Oncol Rep* 10(3):555–560.
 Okutsu S, Takeda A, Suzuki T, Nakajima Y, Sato J, Suda K, Fukuda M, Usami T, Himiya T, Kusama K, et al. 1993. Expression of *ras-P21* and *ras* gene alteration in pleomorphic adenomas. *J Nihon Univ Sch Dent* 35(3):200–203.
 Papadaki H, Finkelstein SD, Kounelis S, Bakker A, Swalsky PA, Kapadia SB. 1996. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. *Hum Pathol* 27(6):567–572.
 Perrone F, Oggionni M, Birindelli S, Suardi S, Tabano S, Romano R, Moiraghi ML, Bimbi G, Quattrone P, Cantu G, Pierotti MA, Licitra L, Pilotti S. 2003. TP53, P14arf, P16ink4a and H-Ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. *Int. J. Cancer* 105:196–203.
 Russo A, Migliavacca M, Zanna I, Valerio MR, Latteri MA, Grassi N, Pantuso G, Salerno S, Dardanoni G, Albanese I, La Farina M, Tomasino RM, Gebbia N, Bazan V. 2002. p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up. *Cancer Epidemiol Biomarkers Prev* 11:1322–1331.
 Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. 2005. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. *Ann Oncol* 16(Suppl. 4):iv44–iv49.
 Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. 1996. Role of the INK4 locus in tumor suppression and cell mortality. *Cell* 85(1):27–37.
 Sherr CJ, McCormick F. 2002. The RB and p53 pathways in cancer. *Cancer Cell* 2:103–112.
 Soini Y, Autio-Harmainen H. 1993. Synthesis and degradation of base membranes in benign and malignant salivary gland tumors. *J Pathol* 170:291–296.
 Steele RJ, Thompson AM, Hall PA, Lane DP. 1998. The p53 tumour suppressor gene. *Br J Surg* 85:1460–1467.
 Su L, Morgan PR, Harrison DL, Waseem A, Lane EB. 1993. Expression of keratin mRNA in normal salivary gland epithelium and pleomorphic adenoma. *J Pathol* 171:173–181.
 Weber A, Langhanki L, Schutz A, Gerstner A, Bootz F, Wittekind C, Tannapfel A. 2002a. Expression profiles of p53, p63, and p73 in benign salivary gland tumors. *Virchows Arch* 441(5):428–436.

- Weber A, Langhanki L, Schutz A, Wittekind C, Bootz F, Tannapfel A. 2002b. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland. *J Pathol* 198:326–334.
- Welsh RA, Meyer AT. 1968. Mixed tumors of salivary gland. *Arch Pathol* 85:433–447.
- Yamamoto Y, Kishimoto Y, Virmani AK, Smith A, Vuitch F, Albores-Saavedra J, Gazdar AF. 1996. Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. *Human Pathology* 27: N.8.
- Yoo J, Robinson RA. 2000. H-ras mutations in salivary gland mucoepidermoid carcinomas. *Cancer* 88: N.3.
- Zhang DS, Bian CR, Wang PY, Yuan XL, Wang JY. 2004. Analysis of p53 gene mutation in salivary adenoid cystic carcinoma. *Shanghai Kou Qiang Yi Xue* 13(5):396–398.
- Zheng W, Shu XO, Ji BT, Gao YT. 1996. Diet and other risk factors for cancer of the salivary glands: A population-based case-control study. *Int J Cancer* 67(2): 194–198.